Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

被引：1
|
作者：
Lachowiez, Curtis A. [1 ]
Ravikumar, Vishvaas I. [1 ]
Othman, Jad [1 ,2 ,3 ,4 ]
O'Nions, Jenny [2 ,5 ]
Peters, Daniel T. [3 ,6 ]
Mcmahon, Christine [7 ]
Swords, Ronan [1 ]
Cook, Rachel [1 ]
Saultz, Jennifer N. [1 ]
Tyner, Jeffrey W. [1 ]
Dillon, Richard [2 ,3 ]
Zeidner, Joshua F. [6 ]
Pollyea, Daniel A. [7 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol Med Oncol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA
[2] Kings Coll London, Dept Med & Mol Genet, London, England
[3] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
[4] Univ Sydney, Fac Med & Hlth, Sydney, Australia
[5] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England
[6] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[7] Univ Colorado, Sch Med, Div Hematol, Aurora, CO USA
来源：
BLOOD | 2024年 / 144卷 / 26期
关键词：
AZACITIDINE;
D O I：
10.1182/blood.2024026925
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2788 / 2792
页数：5
相关论文
共 50 条
  • [1] Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
    Hoff, Fieke W.
    Blum, William G.
    Huang, Ying
    Li Welkie, Rina
    Swords, Ronan T.
    Traer, Elie
    Stein, Eytan M.
    Lin, Tara L.
    Archer, Kellie J.
    Patel, Prapti A.
    Collins, Robert H.
    Baer, Maria R.
    Duong, Vu H.
    Arellano, Martha L.
    Stock, Wendy
    Odenike, Olatoyosi
    Redner, Robert L.
    Kovacsovics, Tibor
    Deininger, Michael W.
    Zeidner, Joshua F.
    Olin, Rebecca L.
    Smith, Catherine C.
    Foran, James M.
    Schiller, Gary J.
    Curran, Emily K.
    Koenig, Kristin L.
    Heerema, Nyla A.
    Chen, Timothy
    Martycz, Molly
    Stefanos, Mona
    Marcus, Sonja G.
    Rosenberg, Leonard
    Druker, Brian J.
    Levine, Ross L.
    Burd, Amy
    Yocum, Ashley O.
    Borate, Uma M.
    Mims, Alice S.
    Byrd, John C.
    Madanat, Yazan F.
    BLOOD ADVANCES, 2024, 8 (20) : 5297 - 5305
  • [2] Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
    Bewersdorf, Jan Philipp
    Derkach, Andriy
    Gowda, Lohith
    Menghrajani, Kamal
    DeWolf, Susan
    Ruiz, Josel D.
    Ponce, Doris M.
    Shaffer, Brian C.
    Tamari, Roni
    Young, James W.
    Jakubowski, Ann A.
    Gyurkocza, Boglarka
    Chan, Alexander
    Xiao, Wenbin
    Glass, Jacob
    King, Amber C.
    Cai, Sheng F.
    Daniyan, Anthony
    Famulare, Christopher
    Cuello, Bernadette M.
    Podoltsev, Nikolai A.
    Roshal, Mikhail
    Giralt, Sergio
    Perales, Miguel-Angel
    Seropian, Stuart
    Cho, Christina
    Zeidan, Amer M.
    Prebet, Thomas
    Stein, Eytan M.
    Tallman, Martin S.
    Goldberg, Aaron D.
    Stahl, Maximilian
    LEUKEMIA & LYMPHOMA, 2021, 62 (14) : 3394 - 3401
  • [3] Optimal therapeutic strategies in relapsed/refractory AML with prior exposure to venetoclax-based therapy
    Bawek, Sawyer
    Burwinkel, Matthew
    Patel, Prutha
    Wang, Katy
    Attwood, Kristopher
    Cronin, Tara
    Fos, Melissa
    Green, Steven
    Sung, Pamela J.
    Thompson, James E.
    Griffiths, Elizabeth A.
    Wang, Eunice S.
    Przespolewski, Amanda C.
    LEUKEMIA RESEARCH, 2025, 150
  • [4] A Phase 1 Study of Adding Pitavastatin to Venetoclax-Based Therapy in AML and CLL/SLL
    Brem, Elizabeth A.
    O'Brien, Susan M.
    Becker, Pamela S.
    Jeyakumar, Deepa
    Pinter-Brown, Lauren C.
    Kirk, Christina
    Taylor, Thomas
    Johnson, Blake
    Osorio, Stephanie
    Buono, Roberta
    Fruman, David A.
    BLOOD, 2023, 142
  • [5] Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy
    Eide, Christopher A.
    Kurtz, Stephen E.
    Kaempf, Andy
    Long, Nicola
    Joshi, Sunil K.
    Nechiporuk, Tamilla
    Huang, Ariane
    Dibb, Charles
    Bottomly, Daniel
    McWeeney, Shannon K.
    Chang, Bill H.
    Druker, Brian J.
    Tyner, Jeffrey W.
    BLOOD, 2022, 140 : 1025 - 1027
  • [6] Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients
    Yang, Ting-Ting
    Song, Xiao-Lu
    Zhao, Yan-Min
    Ye, Bao-Dong
    Luo, Yi
    Xiao, Hao-Wen
    Chen, Yi
    Fu, Hua-Rui
    Yu, Jian
    Liu, Li-Zhen
    Lai, Xiao-Yu
    Ye, Yi-Shan
    Lan, Jian-Ping
    Huang, He
    Shi, Ji-Min
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2731 - 2741
  • [7] Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients
    Ting-Ting Yang
    Xiao-Lu Song
    Yan-Min Zhao
    Bao-Dong Ye
    Yi Luo
    Hao-Wen Xiao
    Yi Chen
    Hua-Rui Fu
    Jian Yu
    Li-Zhen Liu
    Xiao-Yu Lai
    Yi-shan Ye
    Jian-Ping Lan
    He Huang
    Ji-Min Shi
    Annals of Hematology, 2022, 101 : 2731 - 2741
  • [8] Venetoclax-based therapy as a bridge to allogeneic hematopoietic cell transplantation in children with relapsed/refractory AML
    Thomas Pfeiffer
    Ying Li
    Emily Ashcraft
    Seth E. Karol
    Jeffrey E. Rubnitz
    Rebecca Epperly
    Renee Madden
    Ewelina Mamcarz
    Esther Obeng
    Amr Qudeimat
    Akshay Sharma
    Ashok Srinivasan
    Ali Suliman
    Aimee C. Talleur
    M. Paulina Velasquez
    Stephen Gottschalk
    Brandon M. Triplett
    Swati Naik
    Bone Marrow Transplantation, 2023, 58 : 328 - 331
  • [9] Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
    Joshi, Maansi
    Cook, Joselle
    McCullough, Kristen
    Nanaa, Ahmad
    Gangat, Naseema
    Foran, James M.
    Murthy, Hemant S.
    Kharfan-Dabaja, Mohamed A.
    Sproat, Lisa
    Palmer, Jeanne
    Pardanani, Animesh
    Tefferi, Ayalew
    Begna, Kebede
    Elliot, Michelle
    Al-Kali, Aref
    Patnaik, Mrinal
    Shah, Mithun V.
    Hogan, William J.
    Litzow, Mark R.
    Alkhateeb, Hassan B.
    BLOOD CANCER JOURNAL, 2021, 11 (03)
  • [10] Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
    Unglaub, Julia M.
    Schlenk, Richard F.
    Hanoun, Maher
    Reinhardt, H. Christian
    Middeke, Jan Moritz
    Schaefer-Eckart, Kerstin
    Steffen, Bjoern
    Krause, Stefan W.
    Schliemann, Christoph
    Kaufmann, Martin
    Haenel, Mathias
    Jost, Edgar
    Crysandt, Martina
    Fransecky, Lars
    Einsele, Hermann
    Kraus, Sabrina
    Niemann, Dirk
    Neubauer, Andreas
    Seggewiss-Bernhardt, Ruth
    Scholl, Sebastian
    Klein, Stefan
    Schmid, Christoph
    Schaich, Markus
    Platzbecker, Uwe
    Baldus, Claudia D.
    Bornhaeuser, Martin
    Serve, Hubert
    Roellig, Christoph
    Kramer, Michael
    Katelari, Elena
    Janssen, Maike
    Pabst, Caroline
    Luft, Thomas
    Dreger, Peter
    Mueller-Tidow, Carsten
    Sauer, Tim
    BLOOD, 2022, 140 : 3317 - 3319
12345